Moderna And GSK Hit By Declining RSV Vaccines Expectations
Executive Summary
The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.